Ex vivo validation of osteogenic efficacy in a bioceramic dual drug-delivery system.

Alendronate (ALN) is widely employed against skeletal disorders, but its low oral bioavailability and prolonged skeletal retention necessitate high systemic doses that carry significant risk. The research team previously developed a novel bioceramic…

Preview only. Read the full abstract at the source